



PRESS RELEASE

Collectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018

June 27, 2018 (4:30pm CEST) – New York (N.Y.) – Collectis S.A. Annual General Meeting (Euronext Growth: ALCLS - Nasdaq: CLLS) was held on Tuesday, June 26, 2018 in Paris, at its head office.

At the meeting, during which more than 64% of voting rights were exercised, all the resolutions for which the management recommended a vote in favor, were adopted.

The resolutions adopted by Collectis' shareholders included notably:

- Approval of the annual financial statements for the financial year ended December 31, 2017;
- Approval of the consolidated financial statements for the financial year ended December 31, 2017.
- Renewal of the term of office of Director of Mr. André Choulika, Mr. David Sourdivé and Mr. Alain Godard;
- Renewal of the term office of Ernst & Young et Autres, and J.M.H. Conseil as Company's Statutory Auditors.

The full results of the vote can be examined on the company's website www.collectis.com/en/investors/general-meetings/

About Collectis

Collectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Collectis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets. Collectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.collectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark owned by Collectis.

For further information, please contact:

Media contacts:

Jennifer Moore, VP of Communications, 917-580-1088, media@collectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241,
ckasunich@kcsa.com

IR contact:

Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,
simon.harnest@collectis.com

###